Veopoz Receives FDA Approval As First Treatment For Children And Adults With CHAPLE Disease
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals has received FDA approval for Veopoz, the first treatment for children and adults with CHAPLE disease. This approval represents the 10th FDA-approved medicine invented by Regeneron. The pre-approval inspection issues related to the aflibercept 8 mg biologics license application (BLA) have also been addressed, with FDA action expected in the next few weeks.
August 18, 2023 | 5:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron's new FDA approval for Veopoz could potentially boost its stock in the short term. The resolution of pre-approval inspection issues related to the aflibercept 8 mg BLA also bodes well for the company.
FDA approval of a new drug typically leads to increased investor confidence and can boost a company's stock. The resolution of pre-approval inspection issues related to another drug application also removes a potential hurdle for the company, which could further positively impact the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100